Three keys. Three receptors. One compound.
Retatrutide is an investigational triple-agonist* that binds the GLP-1, GIP, and glucagon receptors simultaneously. This is the defining feature: by activating the glucagon receptor in addition to the incretin pair, it is associated in clinical trials with direct effects on energy expenditure*, not only appetite suppression.
Clinical studies have explored retatrutide at multiple dose tiers with a structured titration schedule, mirroring the approach used for earlier GLP-1 compounds.
Because the triple-receptor profile is new, retatrutide sits at the investigational frontier of the category, and protocols are designed around conservative titration* rather than rapid ramp.
Every lot ships with an independent Certificate of Analysis on file. Below is the format your lot's COA arrives in — HPLC chromatogram, identity, endotoxin, the works. Request the document for the exact lot you receive.
request your lot's coa →“Vial arrived sealed, label was clean, lot code matched the COA on the site. Reconstitution was straightforward. Process is solid end to end.”
“Looked up my lot's HPLC trace before opening. The fact that the COA is searchable by lot is the reason I bought from vitalitiRX over the alternatives I'd been considering.”
“Discreet packaging, fast Canadian shipping, vial integrity intact. Customer service answered a reconstitution question in under an hour. Would order again.”
reviews describe product + service only — purity, packaging, lot traceability, fulfilment, COA access. per health canada guidance, claims about diagnosis, treatment, or specific outcomes are edited out before publication.
Research use only. Not for human consumption. Not approved by Health Canada for therapeutic use.
